Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.42 |
| ▸ | GLS | O94925 | 7/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887486 | 0.83 | GLS (0.47) | GLSBRAF | |
| SCHEMBL16879523 | 0.82 | GLS (0.49) | RIPK1RIPK3GLSNLRP3 | |
| SCHEMBL16887479 | 0.82 | BRAF (0.43) | GLSP2RY14BRAFNLRP3 | |
| SCHEMBL16879071 | 0.82 | GLS (0.43) | RIPK1RIPK3GLSP2RY14BRAF | |
| SCHEMBL16887490 | 0.78 | GLS (0.46) | GLSP2RY14 | |
| SCHEMBL16879519 | 0.78 | NPC1 (0.52) | RIPK1RIPK3GLSP2RY14BRAF | |
| SCHEMBL15728060 | 0.78 | GLS (0.53) | GLS | |
| SCHEMBL29679027 | 0.78 | GLS (0.53) | GLS | |
| SCHEMBL16887474 | 0.77 | BRAF (0.48) | GLSP2RY14BRAFNLRP3 | |
| SCHEMBL16887482 | 0.76 | GLS (0.46) | GLSP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS AG (CH) | 2016-10-13 | — | — | US | disclosed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297761-A1 | NOVEL INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | RIPK1 2126/4885RIPK3 2079/4885GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.